CXCL17 and neoplasm: CXCL17 was preferentially expressed in the aggressive types of breast, lung and gastrointestinal cancer cells, resulted in the accumulation of immature CD11b+Gr1+ myeloid-derived suppressor cells at tumor sites (17, 47).